Fred Hutchinson

Avelumab switch maintenance prolonged OS among patients with advanced urothelial carcinoma whose disease did not progress after first-line chemotherapy, according to study results presented during the ASCO20 Virtual Scientific Program.

For Laura Q.M. Chow, MD, medical oncologist at Seattle Cancer Care Alliance and professor of medicine in the division of medical oncology at the University of Washington, there is still much to be done to improve the quality of life and survival of patients with lung cancer until it is eradicated — starting with identification of better biomarkers to personalize therapy and development of novel therapies to improve response and survival in clinical trials.

ASH Research Collaborative’s Data Hub launched an international data registry to help inform care for individuals with blood cancers and COVID-19.

ORLANDO — Myeloablative conditioning before hematopoietic stem cell transplantation conferred a long-term survival advantage compared with reduced-intensity conditioning among patients with acute myeloid leukemia or myelodysplastic syndrome, according to extended follow-up of the randomized phase 3 MAvRIC trial presented at TCT | Transplantation & Cellular Therapy Meetings.

ORLANDO — Patients with relapsed or refractory large B-cell non-Hodgkin lymphoma can be successfully treated and monitored in the outpatient setting with the chimeric antigen receptor T-cell therapy lisocabtagene maraleucel, according to study results presented at TCT | Transplantation & Cellular Therapy Meetings.

ORLANDO — CPX-351 extended OS compared with 7 + 3 chemotherapy among patients with acute myeloid leukemia and myelodysplasia-related changes who achieved complete remission or complete remission with incomplete neutrophil or platelet recovery, according to an exploratory subgroup analysis of a phase 3 study presented at TCT | Transplantation & Cellular Therapy Meetings.

ORLANDO — Hematopoietic stem cell transplantation after treatment with quizartinib or salvage chemotherapy extended survival among patients with FLT-internal tandem duplication-mutated relapsed or refractory acute myeloid leukemia, according to post-hoc analyses of the randomized QuANTUM-R study presented at TCT | Transplantation & Cellular Therapy Meetings.

ORLANDO — Higher total body irradiation dose appeared associated with significantly higher risk for nonrelapse mortality and overall mortality among patients with non-Hodgkin lymphoma who underwent reduced-intensity conditioning prior to allogeneic hematopoietic stem cell transplantation, according to study results presented at TCT | Transplantation & Cellular Therapy Meetings.

In 1984, a teenage boy was lying in his hospital bed, his body ravaged by acute graft-versus host disease.

Patients who received allogeneic hematopoietic stem cell transplants between 2013 and 2017 demonstrated substantial improvement in survival outcomes and fewer complications than those who underwent transplantation a decade earlier, according to results of a retrospective study published in Annals of Internal Medicine.